**Core Concept**
Lipoprotein(a) [Lp(a)] is a type of lipoprotein that carries cholesterol in the blood. Elevated levels of Lp(a) are associated with an increased risk of atherosclerotic cardiovascular disease. Therefore, lipid-lowering drugs that reduce Lp(a) levels are of particular interest in managing cardiovascular risk.

**Why the Correct Answer is Right**
Niacin, also known as nicotinic acid, is a lipid-lowering agent that acts by inhibiting the breakdown of lipids in the liver, thereby reducing the production of very-low-density lipoprotein (VLDL) and low-density lipoprotein (LDL) cholesterol. Additionally, niacin has a unique property of reducing the levels of lipoprotein(a) [Lp(a)] in the blood. This is achieved through the inhibition of apolipoprotein(a) [apo(a)] synthesis, which is the protein component of Lp(a).

**Why Each Wrong Option is Incorrect**
**Option A:** Statins are a class of lipid-lowering drugs that primarily inhibit HMG-CoA reductase, an enzyme involved in the biosynthesis of cholesterol. While statins are effective in reducing LDL cholesterol levels, they do not have a significant impact on Lp(a) levels.

**Option B:** Fibrates are a class of lipid-lowering drugs that primarily activate peroxisome proliferator-activated receptor-alpha (PPAR-alpha), which regulates the expression of genes involved in lipid metabolism. Fibrates are effective in reducing triglyceride levels and increasing HDL cholesterol levels, but they do not have a significant effect on Lp(a) levels.

**Option C:** Ezetimibe is a lipid-lowering drug that inhibits the absorption of cholesterol in the small intestine. While ezetimibe is effective in reducing LDL cholesterol levels, it does not have a significant impact on Lp(a) levels.

**Option D:** Omega-3 fatty acids are a type of dietary supplement that have been shown to have anti-inflammatory and lipid-lowering effects. However, they do not have a significant impact on Lp(a) levels.

**Clinical Pearl / High-Yield Fact**
Niacin is a unique lipid-lowering agent that reduces Lp(a) levels through the inhibition of apo(a) synthesis, making it a valuable addition to the treatment of patients with elevated Lp(a) levels and cardiovascular risk.

**Correct Answer: C. Niacin**